Pulmonary function tests (PFTs) are invaluable tools in the diagnosis, monitoring, and management of respiratory diseases. The interpretation of these tests, however, can be complex and challenging, necessitating a comprehensive understanding for accurate clinical application.
PFTs primarily assess three parameters: lung volumes, airflow, and gas exchange. Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and their ratio (FEV1/FVC) are the key indicators of airflow. Total Lung Capacity (TLC), Residual Volume (RV), and Functional Residual Capacity (FRC) depict lung volumes. Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) measures gas exchange.
Spirometry is the cornerstone of PFTs. Normal FEV1/FVC ratio is above 0.7. A decreased ratio suggests obstructive disease, while normal or increased ratio with decreased volumes indicates restrictive pattern. The severity of obstruction or restriction is classified based on FEV1 or FVC percentages of predicted values.
Increased RV and FRC suggest air trapping, common in obstructive diseases. Decreased TLC indicates restrictive disease. A reduced DLCO points towards impaired gas exchange, seen in interstitial lung disease and pulmonary vascular disorders. However, it might be normal in pure airway diseases like asthma.
Interpretation of PFTs should always be integrated with clinical context and other investigations. For instance, a normal DLCO in a patient with reduced volumes and FEV1/FVC ratio may favor a diagnosis of asthma over COPD. Conversely, a reduced DLCO in a patient with normal spirometry could suggest early interstitial lung disease.
Interpreting PFTs is a vital skill for healthcare professionals involved in respiratory care. A thorough understanding of the basic parameters, coupled with an ability to integrate these results with clinical context, can greatly enhance diagnostic accuracy and patient management.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation